Cargando…
Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675433/ https://www.ncbi.nlm.nih.gov/pubmed/36414222 http://dx.doi.org/10.1016/j.autrev.2022.103233 |
| _version_ | 1784833371405287424 |
|---|---|
| author | Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj |
| author_facet | Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj |
| author_sort | Mungmunpuntipantip, Rujittika |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9675433 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96754332022-11-21 Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj Autoimmun Rev Article Elsevier B.V. 2023-02 2022-11-19 /pmc/articles/PMC9675433/ /pubmed/36414222 http://dx.doi.org/10.1016/j.autrev.2022.103233 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence |
| title | Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence |
| title_full | Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence |
| title_fullStr | Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence |
| title_full_unstemmed | Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence |
| title_short | Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and COVID19 vaccination: Correspondence |
| title_sort | severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy and covid19 vaccination: correspondence |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675433/ https://www.ncbi.nlm.nih.gov/pubmed/36414222 http://dx.doi.org/10.1016/j.autrev.2022.103233 |
| work_keys_str_mv | AT mungmunpuntipantiprujittika severetreatmentrefractoryantibodypositiveautoimmuneautonomicganglionopathyandcovid19vaccinationcorrespondence AT wiwanitkitviroj severetreatmentrefractoryantibodypositiveautoimmuneautonomicganglionopathyandcovid19vaccinationcorrespondence |